Creative Planning decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.1% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 93,948 shares of the company’s stock after selling 2,000 shares during the period. Creative Planning owned 0.21% of Amphastar Pharmaceuticals worth $1,678,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of the company. Municipal Employees Retirement System of Michigan increased its position in shares of Amphastar Pharmaceuticals by 3.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 8,200 shares of the company’s stock worth $119,000 after buying an additional 290 shares during the period. Mason Street Advisors LLC increased its position in Amphastar Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 8,394 shares of the company’s stock valued at $122,000 after buying an additional 549 shares during the last quarter. Karp Capital Management Corp purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at $193,000. MARSHALL WACE ASIA Ltd purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at $215,000. Finally, Marshall Wace North America L.P. purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at $215,000. 44.02% of the stock is owned by institutional investors.
Amphastar Pharmaceuticals, Inc. (AMPH) traded down 2.49% on Friday, reaching $14.89. The company’s stock had a trading volume of 246,952 shares. The company has a market capitalization of $683.60 million, a price-to-earnings ratio of 193.38 and a beta of 1.65. The stock has a 50 day moving average price of $17.33 and a 200-day moving average price of $15.92. Amphastar Pharmaceuticals, Inc. has a 1-year low of $12.05 and a 1-year high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.43%. The company had revenue of $65.20 million during the quarter, compared to the consensus estimate of $63.40 million. During the same quarter last year, the firm posted $0.23 EPS. The company’s quarterly revenue was down 4.1% on a year-over-year basis. Equities analysts predict that Amphastar Pharmaceuticals, Inc. will post $0.40 earnings per share for the current fiscal year.
Amphastar Pharmaceuticals announced that its Board of Directors has authorized a stock repurchase program on Wednesday, August 9th that allows the company to repurchase $20.00 million in shares. This repurchase authorization allows the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: “Creative Planning Has $1.68 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/08/11/creative-planning-sells-2000-shares-of-amphastar-pharmaceuticals-inc-nasdaqamph-updated-updated-updated.html.
Several equities analysts recently weighed in on AMPH shares. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. Jefferies Group LLC lowered their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Wells Fargo & Company reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Saturday, July 22nd. Finally, Piper Jaffray Companies set a $20.00 price objective on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, July 29th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $20.00.
In related news, Director Jason B. Shandell sold 11,482 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $16.92, for a total transaction of $194,275.44. Following the completion of the sale, the director now owns 241,342 shares of the company’s stock, valued at approximately $4,083,506.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael A. Zasloff sold 15,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $17.01, for a total transaction of $255,150.00. Following the completion of the sale, the director now owns 47,411 shares of the company’s stock, valued at approximately $806,461.11. The disclosure for this sale can be found here. Insiders have sold a total of 36,482 shares of company stock valued at $620,125 in the last ninety days. 11.10% of the stock is currently owned by insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
What are top analysts saying about Amphastar Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amphastar Pharmaceuticals Inc. and related companies.